DREAM Trial

- January 6, 2009

Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.

CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!

Presentation

"DREAM Trial"

Prof. Hertzel Gerstein (biography)
English - 2005-04-15 - 31 minutes

(15 slides)

Summary :
The objective of the dream trial (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) is to determine the efficacy of ramipril and/or rosiglitazone on prevention of diabetes in non-diabetic individuals with impaired glucose tolerance or impaired fasting glucose.

Prof Gerstein presents the design of the DREAM trial in detail and reviews the key questions which this study is expected to answer.

Copyright © 2005 E-MedHosting.com Inc.

Learning objectives :
After viewing this presentation, participants will be able to discuss:
- The objectives of the DREAM trial;
- The study design of the DREAM trial.

Login

	Username :
	Password :

	Lost your password?

Search our website

	Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes.

Social

Let others know about this presentation.

	Del.icio.us
	Digg!

ezCME: HIV - Insulin Resistance - C-Reactive Protein (CRP) - ADHD - Sleep Disorder - Prostate Health - Hemophilia - Transplantation

Copyright © 2002-2009 E-MedHosting.com. All rights reserved. Disclaimer | Sponsor Disclaimer
Powered by Multiwebcast - webcast services

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.